JP Morgan Chase’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.56M | Sell |
19,000
-15,000
| -44% | -$2.76M | ﹤0.01% | 3631 |
|
|
2025
Q4 | $5.98M | Buy |
+34,000
| New | +$5.55M | ﹤0.01% | 3145 |
|
|
2025
Q2 | – | Sell |
-20,000
| Closed | -$2.74M | – | 7086 |
|
|
2025
Q1 | $2.74M | Sell |
20,000
-10,000
| -33% | -$1.43M | ﹤0.01% | 3626 |
|
|
2024
Q4 | $4.59M | Buy |
30,000
+21,000
| +233% | +$3.54M | ﹤0.01% | 3432 |
|
|
2024
Q3 | $1.74M | Hold |
9,000
| – | – | ﹤0.01% | 4104 |
|
|
2024
Q2 | $2.09M | Hold |
9,000
| – | – | ﹤0.01% | 3755 |
|
|
2024
Q1 | $1.94M | Sell |
9,000
-40,600
| -82% | -$9.51M | ﹤0.01% | 3866 |
|
|
2023
Q4 | $12.8M | Buy |
49,600
+5,600
| +13% | +$1.38M | ﹤0.01% | 2228 |
|
|
2023
Q3 | $11.3M | Buy |
44,000
+16,800
| +62% | +$4.49M | ﹤0.01% | 2154 |
|
|
2023
Q2 | $7.75M | Sell |
27,200
-10,000
| -27% | -$2.98M | ﹤0.01% | 2508 |
|
|
2023
Q1 | $10.3M | Sell |
37,200
-35,900
| -49% | -$9.93M | ﹤0.01% | 2255 |
|
|
2022
Q4 | $20.2M | Buy |
73,100
+29,200
| +67% | +$8.25M | ﹤0.01% | 1667 |
|
|
2022
Q3 | $11.7M | Buy |
43,900
+13,400
| +44% | +$2.85M | ﹤0.01% | 2026 |
|
|
2022
Q2 | $6.22M | Buy |
30,500
+18,000
| +144% | +$3.68M | ﹤0.01% | 2582 |
|
|
2022
Q1 | $2.63M | Sell |
12,500
-50,500
| -80% | -$11M | ﹤0.01% | 3537 |
|
|
2021
Q4 | $15.1M | Buy |
63,000
+29,400
| +88% | +$7.56M | ﹤0.01% | 2072 |
|
|
2021
Q3 | $9.51M | Sell |
33,600
-28,700
| -46% | -$9.41M | ﹤0.01% | 2426 |
|
|
2021
Q2 | $21.6M | Buy |
62,300
+52,300
| +523% | +$15.8M | ﹤0.01% | 1773 |
|
|
2021
Q1 | $2.8M | Hold |
10,000
| – | – | ﹤0.01% | 3445 |
|
|
2020
Q4 | $2.45M | Buy |
+10,000
| New | +$2.58M | ﹤0.01% | 3339 |
|
|
2020
Q2 | – | Sell |
-44,300
| Closed | -$14M | – | 5373 |
|
|
2020
Q1 | $14M | Sell |
44,300
-60,600
| -58% | -$18.4M | ﹤0.01% | 1477 |
|
|
2019
Q4 | $31.1M | Buy |
104,900
+29,100
| +38% | +$8.07M | 0.01% | 1255 |
|
|
2019
Q3 | $17.6M | Sell |
75,800
-25,900
| -25% | -$6.03M | ﹤0.01% | 1685 |
|
|
2019
Q2 | $24.4M | Sell |
101,700
-22,700
| -18% | -$5.24M | ﹤0.01% | 1425 |
|
|
2019
Q1 | $29.4M | Sell |
124,400
-85,900
| -41% | -$27M | 0.01% | 1267 |
|
|
2018
Q4 | $63.3M | Sell |
210,300
-47,350
| -18% | -$15.1M | 0.01% | 809 |
|
|
2018
Q3 | $91M | Buy |
257,650
+35,900
| +16% | +$12.4M | 0.02% | 745 |
|
|
2018
Q2 | $64.4M | Buy |
221,750
+37,850
| +21% | +$10.6M | 0.01% | 850 |
|
|
2018
Q1 | $50.4M | Sell |
183,900
-204,300
| -53% | -$63.4M | 0.01% | 932 |
|
|
2017
Q4 | $124M | Buy |
388,200
+129,900
| +50% | +$41.7M | 0.03% | 557 |
|
|
2017
Q3 | $80.1M | Buy |
258,300
+159,200
| +161% | +$47.1M | 0.02% | 721 |
|
|
2017
Q2 | $26.9M | Sell |
99,100
-116,700
| -54% | -$30.9M | 0.01% | 1254 |
|
|
2017
Q1 | $59M | Buy |
215,800
+36,150
| +20% | +$10.2M | 0.01% | 862 |
|
|
2016
Q4 | $50.9M | Buy |
179,650
+142,350
| +382% | +$42.2M | 0.01% | 883 |
|
|
2016
Q3 | $11.7M | Sell |
37,300
-1,864
| -5% | -$552K | ﹤0.01% | 1694 |
|
|
2016
Q2 | $9.47M | Buy |
39,164
+31,234
| +394% | +$8.23M | ﹤0.01% | 1868 |
|
|
2016
Q1 | $2.06M | Sell |
7,930
-25,005
| -76% | -$6.61M | ﹤0.01% | 2679 |
|
|
2015
Q4 | $10.1M | Buy |
32,935
+8,688
| +36% | +$2.5M | ﹤0.01% | 1818 |
|
|
2015
Q3 | $7.08M | Buy |
24,247
+21,612
| +820% | +$7.14M | ﹤0.01% | 1999 |
|
|
2015
Q2 | $1.06M | Sell |
2,635
-37,365
| -93% | -$15M | ﹤0.01% | 3253 |
|
|
2015
Q1 | $16.9M | Sell |
40,000
-15,900
| -28% | -$6.27M | ﹤0.01% | 1547 |
|
|
2014
Q4 | $19M | Buy |
55,900
+5,000
| +10% | +$1.62M | ﹤0.01% | 1509 |
|
|
2014
Q3 | $16.8M | Buy |
+50,900
| New | +$16.8M | ﹤0.01% | 1560 |
|
Other funds holding BIIB
VCM
VPM
JP Morgan Chase's BIIB Position: Q1 2026 in Review
JP Morgan Chase increased its Biogen (BIIB) stake by 8.5% in Q1 2026, buying an estimated $29.3M and bringing the position to 2,016,009 shares worth $378M. The position accounts for 0.02% of the portfolio, ranked #484.
JP Morgan Chase first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.47B in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- JP Morgan Chase held 2,016,009 shares of Biogen worth $378M as of Q1 2026.
- JP Morgan Chase bought 158,747 Biogen shares in Q1 2026, an estimated $29.3M.
- Biogen made up 0.02% of JP Morgan Chase's portfolio in Q1 2026, its #484 holding.
- JP Morgan Chase first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- JP Morgan Chase's Biogen position peaked at $2.47B in Q1 2015.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.